Abstract

The aim: To pharmacoeconomic analysis of direct medical costs for self-control of diabetes in Ukraine, Moldova and Georgia. Our observational, cross-sectional study aims at finding out the real costs of covering expenses in order to make decisions on the reimbursement of self-control means. Materials and methods: 1) International and national clinical guidelines for diabetes; 2) information about the prices of glucometers, test strips from online pharmacy services. Systematization, generalization and pharmacoeconomic analysis of direct medical costs were used in the study. Results: Based on the generalization of recommendations on the frequency of blood glucose control, 3 scenarios were identified, according to which the costs were calculated: Type 1 diabetes; Type 2 diabetes (insulin therapy); Type 2 diabetes (oral hypoglycemic therapy). The authors conducted pharmacoeconomic analysis of direct medical costs for self-control of DM for PWD in Ukraine, Moldova and Georgia. The study shows that the lowest cost of self-control is provided in Ukraine, in addition, Ukraine has a wider choice of glucometers and test strips. It was revealed that the pharmaceutical markets for glycometers in the three countries depends on the import of equipment. Conclusions: It is advisable to introduce in Ukraine the reimbursement of self-control devices, namely, glucometers and test strips for all categories of PWD, which will contribute to self-control and, as a result, will be able to prevent the development of complications. Certification of continuous glucose monitoring systems will increase access to new technologies that are already widely used in many countries.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.